

0	- 111-12-12-12-12-12-12-12-12-12-12-12-12-			Complete if Known		
Sub	stitute for form 1449/PTO			Application Number	10/773,792	
IN	FORMATION	ı Di	SCLOSURE	Filing Date	February 6, 2004	
	TATEMENT B			First Named Inventor	Thomas W. DUBENSKY, Jr.	
	IAI EMENT	<i>.</i>	A I LIOATT	Art Unit	1645	
	(Use as many she	ets as	necess ary)	Examiner Name	J. Graser	
Sheet	Sheet 1 of 4		4	Attorney Docket Number	282172002900	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1.	US-2005/0249748-A1	11-10-2005	Dubensky Jr. et al.			
	2.	US-2005/0281783-A1	12-22-2005	Kinch et al.			

		FOREIG	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	3.	FR-2 686 896-A1	08-06-1993	Pasteur Institute		1
	4.	WO-89/09616-A1	10-19-1989	Symbicom Aktiebolag		
	5.	WO-99/29884-A2	06-17-1999	Von Eichel-Streiber et al.		1
	6.	WO-01/27295-A1	04-19-2001	Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts		1
	7.	WO-02/33109-A2, A3	04-25-2002	Bioteknologisk Institut		
	8.	WO-03/083056-A2, A3	10-09-2003	Research Development Foundation		
	9.	WO-2004/011492-A1	02-05-2004	Commonwealth Scientific and Industrial Research Organisation	r	
	10.	WO-2005/009463-A2, A3	02-03-2005	Cerus Corporation		
	11.	WO-2005/037233-A2, A3	04-28-2005	Medimmune, Inc.		
	12.	WO-2005/071088-A2, A3	08-04-2005	Cerus Corporation		
	13.	WO-2005/092372-A2	10-06-2005	Cerus Corporation et al.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, and/or country where published.							
	14.	Barnard, J.P. et al. (February 1999). "Vaccination Against Anthrax with Attenuated Recombinant Strains of <i>Bacillus anthracis</i> That Produce Protective Antigen," <i>Infection and Immunity</i> 67(2):562-567.						
	15.	Bielecki, J. et al. (May 10, 1990). "Bacillus subtilis Expressing a Haemolysin Gene from Listeria monocytogenes Can Grow in Mammalian Cells," Nature 345(6271):175-176.						
	16.	Brockstedt, D. et al. (March 2003). "Recombinant Attenuated Listeria monocytogenes Elicits Robust Cellular Immune Response to Tumor-Associated Antigen in Listeria Immune Mice," Proceedings of the American Association for Cancer Research, 94th Annual Meeting, April 5-9, 2003, Toronto, Ontario, Canada, 44:194, Abstract No. 851, one page.						
	17.	Brockstedt, D.G. (Date Unknown). "Listeria-CEA Vaccine-Infected DC for Cancer Therapy," Abstract for Grant No. 1R43CA108026-01 located at ">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6787426&p_grant_num=1R43C>" last visited June 27, 2004, two pages."						

Cusmisses	
Examiner Date	
Signature Considered	

Cub	estitute for form 1449/PTO			Complete if Known		
Sub	Stitute for form 1445/F10			Application Number	10/773,792	
l in	NFORMATION	N DI	SCLOSURE	Filing Date	February 6, 2004	
	TATEMENT			First Named Inventor	Thomas W. DUBENSKY, Jr.	
				Art Unit	1645	
(Use as many she ets as necess ary)				Examiner Name	J. Graser	
Sheet	2	of 4		Attorney Docket Number	282172002900	

18.	Brockstedt, D.G. et al. (August 2005) "Killed but Metabolically Active Microbes: A New Vaccine Paradigm For Eliciting Effector T-Cell Responses and Protective Immunity," <i>Nature Medicine</i> 11(8):853-860.
19.	Brossier, F. et al. (August 1999). "Antigen Delivery by Attenuated <i>Bacillus anthracis</i> : New Prospects in Veterinary Vaccines," <i>Journal of Applied Microbiology</i> 87(2):298-302.
20.	Brown, D.P et al. (May 1988). "Site-Specific Integration in Saccharopolyspora erythraea and Multisite Integration in Streptomyces lividans of Actinomycete Plasmid pSE101," J. Bacteriology 170(5):2287-2295.
21.	Cohen, S. et al. (August 2000). "Attenuated Nontoxinogenic and Nonencapsulated Recombinant Bacillus anthracis Spore Vaccines Protect Against Anthrax," Infection and Immunity 68(8):4549-4558.
22.	Conradt, P. et al. (1999). "Cytolytic T-Cell Responses to Human Dendritic Cells and Macrophages Infected with <i>Mycobacterium bovis</i> BCG and Recombinant BCG Secreting Listeriolysin," <i>Microbes Infect</i> . 1:753-764.
23.	Dubensky, T.W. (Date Unknown). "Listeria-Based Vaccines for Ovarian Cancer Therapy," Abstract for Grant No. 1R43CA101421-01 located at ">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645288&p_grant_num=1R43CA>" last visited November 3, 2004, two pages."
24.	Dubensky, T.W. (Date Unknown). "Psoralen-Killed, Metabolically-Active Anthrax Vaccine," Abstract for Grant No. 1U01Al061199-01 located at ">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6818020&p_grant_num=1U01Al>" last visited November 3, 2004, two pages."
25.	Dubensky, T.W. (Date Unknown). "Listeria Immunotherapy for Pancreatic and Ovarian Cancer," Abstract for Grant No. 2R44CA101421-02 located at ">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6992210&p_grant_num=2R44C>" last visited December 7, 2005, two pages."
26.	Dubensky, T.W. (Date Unknown). "Psoralen-Killed, Metabolically-Active Anthrax Vaccine," Abstract for Grant No. 5U01AI061199-01 located at ">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6916362&p_grant_num=5U01A>" last visited December 7, 2005, two pages."
27.	Friedman, R.S. et al. (November 2000). "Induction of Human Immunodeficiency Virus (HIV)-Specific CD8 T-Cell Responses by <i>Listeria monocytogenes</i> and a Hyperattenuated <i>Listeria</i> Strain Engineered to Express HIV Antigens," <i>Journal of Virology</i> 74(21):9987-9993.
28.	Giedlin, M. et al. (Date Unknown). "The Living Dead: Vaccines Against Microbial Pathogens Based on Psoralen-Killed Metabolically Active DNA Repair Mutants," Abstract 189 (H) located at http://www.asmbiodefense.org/2004tueabs.asp , last visited November 5, 2004, one page.
29.	Giedlin, M.A. (Date Unknown). "Use of Listeria as Colon Cancer Vaccine Adjuvants," Abstract for Grant No. 1R43CA101378-01 located at ">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6645212&p_grant_num=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc.pum=1R43CA>">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc.pum=1R43CA>">http://crisp.cit.nih.gov/crisp.pum=1R43CA>">http://crisp.cit.nih.gov/crisp.pum=1R43CA>">http://cri
30.	Giedlin, M.A. (Date Unknown). "Listeria-Based Ovarian Cancer Polyepitope Vaccines," Abstract for Grant No. 1R43CA109868-01A1 located at ">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?testkey=6932934&p_grant_num=1R43C>" last visited December 7, 2005, two pages."
31.	Giedlin, M.A. et al. (March 2003). "Therapeutic Immunization with Attenuated Recombinant Listeria monocytogenes Prolongs Survival in a Murine Transplant Model of Melanoma," Proceedings of the American Association for Cancer Research, 94th Annual Meeting, April 5-9, 2003, Toronto, Ontario, Canada, 44:194, Abstract No. 850, one page.
32.	Glomski, I.J. et al. (December 2003). "Listeria monocytogenes Mutants That Fail to Compartmentalize Listerolysin O Activity Are Cytotoxic, Avirulent, and Unable To Evade Host Extracellular Defenses," Infect. Immun. 71(12):6754-6765.

Examiner	Date	
Signature	Considered	
		'

Sub	stitute for form 1449/PTO			Complete if Known		
Sub	suitate for form 1443/PTO			Application Number	10/773,792	
IN	IFORMATIO	N DI	SCLOSURE	Filing Date	February 6, 2004	
	TATEMENT			First Named Inventor	Thomas W. DUBENSKY, Jr.	
	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		2.07	Art Unit	1645	
	(Use as many sh	e ets as	necess ary)	Examiner Name	J. Graser	
Sheet	3	of	4	Attorney Docket Number	282172002900	

33.	Guerry, P. et al. (February 1994). "Development and Characterization of <i>recA M</i> utants of <i>Campylobacter jejuni</i> for Inclusion in Attenuated Vaccines," <i>Infection and Immunity</i> 62(2):426-432.	
34.	Gunn, G.R. et al. (2002). "Recombinant Intra-Cellular Bacteria as Carriers for Tumor Antigens" Chapter 14 <i>In</i> Vaccine Delivery Strategies. Dietrich, G. et al. eds., Horizon Scientific Press: UK. pp. 315-348.	
35.	Guzman, C.A. et al. (June 1998). "Attenuated <i>Listeria monocytogenes Carrier Strains Can</i> Deliver an HIV-1 gp120 T Helper Epitope to MHC Class II-Restricted Human CD4 ⁺ T Cells," <i>European Journal of Immunology</i> 28(6):1807-1814.	
36.	Huang, A.T.C. et al. (May 13, 1994). "Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens," <i>Science</i> 264:961-965.	
37.	International Search Report issued for PCT Application No. PCT/US2004/003671 filed February 6, 2004, mailed April 13, 2005, 12 pages.	
38.	International Search Report issued for PCT Application No. PCT/US2005/002987 filed February 2, 2005, mailed January 19, 2006, 11 pages.	
39.	Kiessling, A. et al. (December 1, 2002). "Prostate Stem Cell Antigen: Identification of Immunogenic Peptides and Assessment of Reactive CD8 ⁺ T Cells in Prostate Cancer Patients," <i>Int. J. Cancer</i> 102(4):390-397.	
40.	Lampson, L.A. et al. (January 1, 1993). "Exploiting the <i>lacZ</i> Reporter Gene for Quantitative Analysis of Disseminated Tumor Growth within the Brain: Use of the <i>lacZ</i> Gene Product as a Tumor Antigen, for Evaluation of Antigenic Modulation, and to Facilitate Image Analysis of Tumor Growth <i>in Situ</i> ," <i>Cancer Research</i> 53(1):176-182.	
41.	Lebrun, M. et al. (August 1996). "Internalin Must be on the Bacterial Surface to Mediate Entry of <i>Listeria monocytogenes</i> into Epithelial Cells," <i>Molecular Microbiology</i> 21(3):579-592.	
42.	Lutz, M.B. et al. (1999). "An Advanced Culture Method For Generating Large Quantities of Highly Pure Dendritic Cells From Mouse Bone Marrow," <i>J. Immunol. Methods</i> 223(1):77-92.	
43.	Mata, M. et al. (January 8, 2001). "Evaluation of a Recombinant <i>Listeria monocytogenes</i> Expressing an HIV Protein that Protects Mice Against Viral Challenge," <i>Vaccine</i> 19(11-12):1435-1445.	
44.	McCloy, E.W. (1951). "Studies on a Lysogenic Bacillus Strain. I. A Bacteriophage Specific for Bacillus anthracis," J. Hyg. 49:114-125.	
45.	Mérino, D. et al. (2002). "A Hypermutator Phenotype Attenuates the Virulence of <i>Listeria monocytogenes</i> in a Mouse Model," <i>Molecular Microbiology</i> 44(3):877-887.	
46.	Mollet, B. et al. (July 1993). "Directed Genomic Integration, Gene Replacement, and Integrative Gene Expression in <i>Streptococcus thermophilus</i> ," <i>J. Bacteriology</i> 175(14):4315-4324.	
47.	Paglia, P. et al. (June 1997). "The Defined Attenuated <i>Listeria monocytogenes Δmpl2</i> Mutant is an Effective Oral Vaccine Carrier to Trigger a Long-Lasting Immune Response Against a Mouse Fibrosarcoma," <i>Eur. J. Immunol.</i> 27(6):1570-1575.	
48.	Reiter, R.E. et al. (February 1998). "Prostate Stern Cell Antigen: A Cell Surface Marker Overexpressed in Prostate Cancer," <i>Proc. Natl. Acad. Sci. USA</i> 95:1735-1740.	
49.	Scheirlinck, T. et al. (September 1989). "Integration and Expression of α-Amylase and Endoglucanase Genes in the <i>Lactobacillus plantarum</i> Chromosome," <i>Applied and Environmental Microbiology</i> 55(9):2130-2137.	
50.	Smith, B.T. et al. (January 2002). "Localization of UvrA and Effect of DNA Damage on the Chromosome of <i>Bacillus subtilis</i> ," <i>Journal of Bacteriology</i> 184(2):488-493.	
51.	Smith, G.A. et al. (September 1995). "Asymmetric Distribution of the Listeria monocytogenes ActA Protein is Required and Sufficient to Direct Actin-Based Motility," Molecular Microbiology 17(5):945-951.	
52.	Snyder, J.T. et al. (July 2004). "Protection Against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8 ⁺ T-Cell Peptide Epitope of Vaccinia and Variola Viruses," <i>J. Virol.</i> 78(13):7052-7060.	

Examiner	Date
Signature	Considered
Signature	Considered

6,1	ostitute for form 1449/PTO			Complete if Known		
l Sur	Stitute for form 1449/PTO			Application Number	10/773,792	
11	NFORMATION	I DI	SCLOSURE	Filing Date	February 6, 2004	
l	TATEMENT E			First Named Inventor	Thomas W. DUBENSKY, Jr.	
ľ	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	1645	
	(Use as many she	ets as	necess ary)	Examiner Name	J. Graser	
Sheet	eet 4 of 4		4	Attorney Docket Number	282172002900	

53.	Stahl, M.L. et al. (May 1984). "Replacement of the <i>Bacillus subtilis</i> Subtilisin Structural Gene with an In Vitro-Derived Deletion Mutation," <i>J. Bacteriology</i> 158(2):411-418.	
54.	Strugnell, R.A. et al. (1990). "Stable Expression of Foreign Antigens from the Chromosome of Salmonella typhimurium Vaccine Strains," Gene 88(1):57-63.	
55.	Svensson, M. et al. (June 1996). "Dendritic Cells Can Process Viable Bacteria and Present Bacterial Antigens on MHC-1 Molecules," <i>Scandinavian Journal of Immunology</i> 43(6):723, Abstract No. 121.	
56.	Van Pinxteren, L.A.H. et al. (2000). "Control of Latent <i>Mycobacterium tuberculosis</i> Infection is Dependent on CD8 T cells," <i>Eur. J. Immunol.</i> 30:3689-3698.	
57.	Welch, M.D. et al. (July 3, 1998). "Interaction of Human Arp2/3 Complex and the <i>Listeria monocytogenes</i> ActA Protein in Actin Filament Nucleation," <i>Science</i> 281:105-108.	
58.	Winterling, K.W. et al. (April 1998). "The Bacillus subtilis DinR Binding Site: Redefinition of the Consensus Sequence," J. Bacteriol. 180(8):2201-2211.	
59.	Wirth, R. et al. (March 1986). "Highly Efficient Protoplast Transformation System for Streptococcus faecalis and a New Escherichia coli-S. faecalis Shuttle Vector," J. Bacteriol. 165(3):831-836.	
60.	Written Opinion issued for PCT Application No. PCT/US2004/003429 filed February 6, 2004, mailed December 7, 2004, 9 pages.	
61.	Written Opinion issued for PCT Application No. PCT/US2004/003671 filed February 6, 2004, mailed April 13, 2005, 15 pages.	
62.	Written Opinion issued for PCT Application No. PCT/US2005/002987 filed February 2, 2005, mailed January 19, 2006, 9 pages.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.